TIDMAVCT

Avacta Group PLC

21 March 2017

Hardman Research: Low response would be positive!

Low response would be positive!: Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. During 2016, Avacta made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. During coming weeks the company is expected to report on the next step in the pre-clinical development process: whether or not Affimer scaffolds are immunogenic. A positive outcome would be a low immune response rate.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/avacta-documents/21.03.17-low-response-would-be-positive!.pdf

 
 To contact us:      Contacts: 
  Hardman & Co        Dr Martin Hall 
  11/12 Tokenhouse    mh@hardmanandco.com 
  Yard                Dr Dorothea Hill 
  London              dmh@hardmanandco.com 
  EC2R 7AS            Dr Gregoire Pave 
                      gp@hardmanabdco.com 
                      Telephone: +44 20 7929 3399 
                      Follow us on Twitter @HardmanandCo

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRADBLFLDXFXBBX

(END) Dow Jones Newswires

March 21, 2017 03:15 ET (07:15 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Avacta Charts.